Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Asia-Pacific Journal of Clinical Oncology|June 26, 2026
Ki-67 Dynamics and Biomarker Conversion as Prognostic Factors in Residual Breast CancerÖmer Faruk Elçiçek, Eyyüp Çavdar, Özge Yalıcı, et al.Journal of Cancer Research and Therapeutics|March 30, 2026
Identifying high-risk groups for recurrence in endometrial cancer: The role of ESMO-ESGO-ESTRO risk classificationÖmer F Elçiçek, Özge Yalici, Kubilay Karaboyun, et al.In Vivo (Athens, Greece)|October 30, 2025
The Prognostic Impact of HER2 Status and Survival Outcomes in Metastatic Triple Negative Breast CancerAlper Turkel, Ece Baydar, Rümeysa Çolak, et al.Expert Opinion on Pharmacotherapy|April 3, 2024
Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) studyElif Şenocak Taşçı, Yasin Kutlu, Ömer Fatih Ölmez, et al.Journal of Chemotherapy (Florence, Italy)|June 21, 2024
Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter studyÖzgecan Dülgar, Sema Türker, Gül Başaran, et al.Journal of Geriatric Oncology|September 8, 2023
PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG studyOkan Avcı, Yakup İriağaç, Eyyüp Çavdar, et al.Turkish Journal of Medical Sciences|November 3, 2022
Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)Cihan Erol, Abdullah Sakin, Tuğba Başoğlu, et al.Medicina (Kaunas, Lithuania)|May 27, 2026
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World AnalysisMustafa Seyyar, Pervin Can Şancı, Abdullah Sakin, et al.Pageof 2